Aurobindo Pharma Stock Gains Over 1.5% to Rs 1,470 After FTC Conditionally Clears $250 Million Lannett Acquisition; Must Divest 4 Generic Products to Quagen Pharma

Aurobindo Pharma Rs 1,461.40 (+1.23%; day high Rs 1,470/+1.82%) on 19 Jun 2026. FTC clears $250M Lannett acquisition with conditions: must divest 4 generic products to Quagen Pharma.

Aurobindo Pharma share price gained over 1.5% to a day high of Rs 1,470 on 19 June 2026 after the US Federal Trade Commission cleared the company’s $250 million acquisition of Pennsylvania-based Lannett Company through a consent order that requires Aurobindo Pharma to divest four generic drug products to Quagen Pharmaceuticals LLC, a New Jersey-based generics maker, to resolve anticompetitive concerns. The FTC’s conditional clearance removes a key regulatory hurdle for Aurobindo’s most significant US acquisition in recent years, which gives it a manufacturing base in Indiana, entry into the attention-deficit/hyperactivity disorder medication market and a reshoring positioning ahead of anticipated US pharmaceutical tariffs.

Click Here – Get Free Investment Predictions

Aurobindo Pharma Lannett Acquisition Details

Why the FTC Consent Order Is a Major Positive for Aurobindo Pharma

The FTC’s conditional clearance of the Lannett acquisition is a major positive for Aurobindo Pharma because it removes the largest regulatory uncertainty hanging over the company’s US strategy for FY27 and beyond. The requirement to divest four generic products to Quagen Pharmaceuticals is a manageable condition: Aurobindo Pharma retains the vast majority of Lannett’s business, including the ADHD controlled substance platform, the Indiana manufacturing facility, the generic liquids portfolio and the overall US commercial relationships. The four divested products, while addressing FTC competition concerns, do not materially alter the strategic rationale or financial profile of the deal.

Use the Univest Screener to analyse Aurobindo Pharma’s US business, financials and peer comparison

Three Strategic Benefits of the Lannett Acquisition for Aurobindo Pharma

1. Indiana Manufacturing: The Reshoring Lifeline

The Seymour, Indiana facility is arguably the most valuable strategic asset in the Lannett acquisition for Aurobindo Pharma. With the Trump administration threatening pharmaceutical tariffs of up to 250% on imported drugs, Indian pharma companies face a structural risk to their export-to-US business model. Aurobindo Pharma’s $250 million investment in a US-based manufacturing facility with 3.6 billion tablets per year of capacity effectively creates a tariff-insulated supply source for its US generics customers. This is a direct competitive advantage versus Indian pharma peers who lack domestic US manufacturing.

2. ADHD Generics: Entering a High-Barrier, High-Value Segment

Lannett’s specialty in controlled substance manufacturing, specifically ADHD medicines, opens a market segment where Aurobindo Pharma had zero presence before. Controlled substance manufacturers must meet stringent DEA (Drug Enforcement Administration) compliance standards and maintain secure manufacturing environments, creating high barriers to entry. The limited number of approved manufacturers in this space generates better pricing and margin stability compared to highly commoditised generic tablets. The ADHD market at $15 billion and growing to $19 billion by 2030 provides a large and expanding addressable market for Aurobindo through Lannett’s established platform.

3. FY27 US Revenue Target: How Lannett Accelerates the Path

Aurobindo Pharma has set an ambitious $2 billion US revenue target for FY27. The Lannett acquisition adds an established US generics business with existing commercial relationships, manufacturing capacity and product approvals. While the four divested products will reduce Lannett’s revenue contribution marginally, the net retained business meaningfully accelerates Aurobindo’s path toward the $2 billion milestone. The company is also pursuing biosimilar market opportunities in the US as a second growth driver alongside the Lannett-enhanced generics platform.

Download the Univest iOS App or Univest Android App to track Aurobindo Pharma share price live and get pharma sector expert picks on Univest.

Conclusion

Aurobindo Pharma share price touched a day high of Rs 1,470 (+1.82%) on 19 June 2026 after the US FTC cleared the $250 million Lannett acquisition through a consent order requiring divestiture of four generic products to Quagen Pharmaceuticals. The clearance removes the primary regulatory overhang on Aurobindo’s US strategy, preserves the strategic core of the deal (Indiana facility, ADHD entry, US revenue scale) and positions the company well for its FY27 US revenue target of $2 billion. The stock has partially trimmed gains to Rs 1,461.40 (+1.23%) and remains a key watch in the pharma sector. Consult a SEBI-registered financial advisor before investing.

What is the FTC order on Aurobindo Pharma’s Lannett acquisition?

Ans. The US Federal Trade Commission has cleared Aurobindo Pharma’s $250 million acquisition of Lannett Company through a consent order that requires Aurobindo to divest four different generic drug products to Quagen Pharmaceuticals LLC. The FTC said Aurobindo’s acquisition of Lannett would combine two of a limited number of competitors in markets for four specific generic pharmaceutical products, including drugs used to prevent organ transplant rejection and tablets that treat dry mouth after radiation therapy. The consent order also requires Aurobindo and Lannett to provide transition services to Quagen and subjects the companies to a compliance monitor.

Why did Aurobindo Pharma acquire Lannett Company?

Ans. Aurobindo Pharma announced the $250 million acquisition of Lannett Company in August 2025 for three strategic reasons. First, it gives Aurobindo an entry into the attention-deficit/hyperactivity disorder (ADHD) medication market, where it had no prior presence. Lannett manufactures controlled substances, primarily ADHD medicines, and generic liquids. Second, the deal secures a 425,000 square foot manufacturing facility in Seymour, Indiana, with annual capacity of approximately 3.6 billion tablets, which aligns with Aurobindo’s reshoring strategy ahead of anticipated US pharmaceutical tariffs of up to 250%. Third, it strengthens Aurobindo’s US generics position for its FY27 target of $2 billion in US revenue.

What are the four generic drugs Aurobindo must divest?

Ans. The FTC has not publicly disclosed the exact names of the four generic drug products in the initial consent order, but described them as products ranging from drugs used to prevent organ transplant rejection to tablets that treat dry mouth after radiation therapy. The FTC noted these products are in markets where Aurobindo and Lannett are two of a limited number of competitors, creating anticompetitive concentration if combined without divestiture. Aurobindo must divest these four products to Quagen Pharmaceuticals LLC before completing the Lannett acquisition.

What is Aurobindo Pharma’s share price today on June 19?

Ans. Aurobindo Pharma share price (NSE: AUROPHARMA) hit a day high of Rs 1,470 on June 19, 2026, up approximately 1.82% from the previous close of Rs 1,443.70. The stock opened at Rs 1,454, touched a day low of Rs 1,446.40 and is currently trading at approximately Rs 1,461.40, up approximately 1.23% from the previous close. The day high of Rs 1,470 represents the peak gain triggered by the FTC consent order announcement, after which the stock partially trimmed gains.

What is the ADHD market opportunity for Aurobindo through Lannett?

Ans. The ADHD medication market was valued at approximately $15 billion in 2024 and is expected to grow to approximately $18.6-19 billion by 2030, according to market analyses. Lannett is a manufacturer of controlled substances, primarily ADHD medicines. Aurobindo had no prior presence in the ADHD segment, making the Lannett acquisition a significant vertical expansion. The ADHD market is characterized by fewer generic manufacturers due to the complexity of controlled substance manufacturing and regulatory requirements, making Lannett’s manufacturing capability a strategically valuable asset for Aurobindo.

How does the Lannett acquisition help Aurobindo with US tariff risks?

Ans. The Trump administration has threatened to impose pharmaceutical tariffs of up to 250% on foreign-made drugs, which would significantly impact Indian pharma companies like Aurobindo that manufacture and export to the US from India. The Lannett acquisition, with its Seymour, Indiana manufacturing facility capable of producing 3.6 billion tablets per year, gives Aurobindo a domestic US manufacturing base. This ‘reshoring’ position reduces Aurobindo’s exposure to potential pharmaceutical tariffs by enabling US-made generic drug supply, and aligns with US government procurement preferences for domestically manufactured pharmaceuticals.

What is Aurobindo Pharma’s FY27 US revenue target?

Ans. Aurobindo Pharma has set a target of $2 billion in US revenue for FY27. The company has been expanding its US generics business and the Lannett acquisition is a key pillar of this growth ambition. The Indiana manufacturing facility adds significant production capacity for tablets and liquids, while the ADHD controlled substance capability opens a new high-value segment. Aurobindo had previously said it plans to beat competition in the biosimilars market, adding another potential US revenue growth driver alongside the Lannett-driven generics expansion.

What was the timeline of the Aurobindo Lannett deal?

Ans. Aurobindo announced the $250 million acquisition of Lannett in August 2025. The expected completion timeline was within 12 months of announcement. The deal was delayed by a partial US government shutdown in early 2026, which affected the FTC’s review process. The FTC has now issued its consent order in June 2026, requiring Aurobindo to divest four generic products to Quagen Pharmaceuticals as a condition for clearance. The public has 30 days to submit comments on the proposed consent package before it becomes final, after which the acquisition can be completed.